

# CANCER THERAPEUTIC RESISTANCE

## PROGRESS AND PERSPECTIVES

Thursday, April, 7<sup>th</sup>, 2016

PROGRAM

COSMOCAIXA BARCELONA . C/ISAAC NEWTON, 26

9:00 **Welcome**

9:15 **SESSION 1: IMMUNOLOGY AND CANCER THERAPY**

Chair: **Miquel Àngel Pujana** (ProCURE, ICO, IDIBELL)

9:15 **Chemoimmunotherapy - a New Approach to treat Refractory Prostate and Liver Cancers**  
**Michael Karin**, University of California, San Diego, USA

9:55 **Targeting the Heterogeneity of Cancer with Individualized Neo-epitope Vaccines - Preclinical and Clinical insight**

**Sebastian Kreiter**, Translational Oncology University Medical Center (TRON), Mainz, Germany

10:35 **Viroimmunotherapy for Cancer Treatment**

**Ramon Alemany**, ProCURE, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain

11:00 **Cellular Senescence and Immune Infiltration in HER2-positive Breast Cancers**

**Joaquín Arribas**, Vall d'Hebron Institute of Oncology (VHIO), ICREA, Barcelona, Spain

11:25 **Open Debate**

11:35 **Coffee break**

12:05 **SESSION 2: GENETICS, EPIGENETICS AND MECHANISMS**

Chair: **Oriol Casanovas** (ProCURE, ICO, IDIBELL)

12:05 **Cancer Pharmacoeigenetics: Genes and Drugs**

**Manel Esteller**, Bellvitge Biomedical Research Institute (IDIBELL), ICREA, Barcelona, Spain

12:30 **Searching for New Strategies to treat T-Acute Lymphoblastic Leukemia**

**Anna Bigas**, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain

12:55 **Epigenetic Control of Gene Regulatory Programs in Metastatic Prostate Cancer**

**Alvaro Aytes**, ProCURE, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain

13:20 **Open Debate**

13:30 **Lunch**

COORGANIZED BY:



WITH THE COLLABORATION OF:





International Center  
for Scientific Debate  
BARCELONA



# CANCER THERAPEUTIC RESISTANCE

## PROGRESS AND PERSPECTIVES

Thursday, April , 7<sup>th</sup>, 2016

PROGRAM

COSMOCAIXA BARCELONA . C/ISAAC NEWTON, 26

**14:30 ROUND TABLE: From Precision Medicine to more Effective Treatments. Dealing with Resistance to Anti-cancer Therapies**

Chair: **Josep Corbella**, Health and Science Journalist at La Vanguardia

**Joaquín Arribas**, Director of Preclinical Research at Vall d'Hebron Institute of Oncology, ICREA  
**Gabriel Capellà**, Research and Innovation Program at Department of Health, Generalitat de Catalunya  
**María Victoria Ureña**, Deputy director of Cell Therapy and Regenerative Medicine, National Institute of Health Carlos III

**Nieves Mijimolle**, Member of the board of trustees of the Spanish Association Against Cancer (FCAeccc)

**Alberto Villanueva**, Leader of the Chemoresistance Group at Catalan Institute of Oncology

**Francesc Mitjans**, Member of the board of trustees at CataloniaBio

**16:30 Coffee break**

**17:00 SESSION 3: MOLECULAR CLASSIFICATION AND THERAPEUTIC TARGETING**

Chair: **Josep Tabernero** (VHIO)

**17:00 Dissecting Colorectal Cancer in Multiple Subtypes**

**Rodrigo Dienstmann**, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

**17:25 Co-Activation of STAT3 and Src-Notch Pathways in EGFR Mutant Lung Cancer**

**Rafael Rosell**, Catalan Institute of Oncology (ICO, IGTP), Barcelona, Spain

**17:50 Identification and Therapeutic Targeting of Poor Prognosis Subtypes in Colorectal Cancer**

**Eduard Batlle**, Institute for Research in Biomedicine (IRB), ICREA, Barcelona, Spain

**18:15 Microenvironment-mediated Chemotherapy Resistance in Colorectal Cancer**

**David G Molleví**, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain

**18:40 Open Debate**

**19:00 Welcome Cocktail and CosmoCaixa visit**

COORGANIZED BY:



WITH THE COLLABORATION OF:





**B-DEBATE**

International Center  
for Scientific Debate  
**BARCELONA**



# CANCER THERAPEUTIC RESISTANCE

## PROGRESS AND PERSPECTIVES

**Friday, April, 8<sup>th</sup>, 2016**

PROGRAM

COSMOCAIXA BARCELONA . C/ISAAC NEWTON, 26

- 9:30 SESSION 4: CANCER OMICS AND THERAPEUTICS**  
Chair: **Héctor G. Palmer** (VHIO)
- 9:30 Genomic Analysis of Therapy Response and Resistance**  
**Elaine Mardis**, McDonnell Genome Institute, Washington University, USA
- 10:10 A Stem Cell-like Program in Therapeutic Resistance**  
**Miquel Angel Pujana**, ProCURE, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain
- 10:35 Coffee break**
- 11:05 Patient-derived Tumor Explants as a Robust Pharmacogenomic Platform for Pre-clinic Drug Testing**  
**Carlos Caldas**, University of Cambridge, UK
- 11:45 New Molecular Landscape in CRC. New Therapeutic Landscape?**  
**Ramon Salazar**, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain
- 12:10 Diagnostic and Therapeutic Implications of unconventional Protein secretion in Cancer**  
**Josep Villanueva**, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 12:35 Open Debate**
- 13:00 Lunch**
- 14:00 SESSION 5: MOLECULAR SIGNALING AND MODELS**  
Chair: **Josep Villanueva** (VHIO)
- 14:00 A Vulnerability of BRAF Resistant Melanoma with Potential Clinical Utility**  
**René Bernards**, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
- 14:40 Targeting the MAPK Pathway in K-RAS Mutant Tumors. Challenges and Opportunities**  
**Marlano Barbacid**, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

COORGANIZED BY:



WITH THE COLLABORATION OF:



**B-DEBATE**

International Center  
for Scientific Debate  
**BARCELONA**



# CANCER THERAPEUTIC RESISTANCE

## PROGRESS AND PERSPECTIVES

**Friday, April , 8<sup>th</sup>, 2016**

PRELIMINARY PROGRAM

COSMOCAIXA BARCELONA . C/ISAAC NEWTON, 26

- 15:20 Restoration of DNA homologous recombination functionality as major mechanism of PARP inhibitor resistance in germline BRCA Breast Cancer**  
**Violeta Serra**, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 15:45 Ortho-xenograft Models and Personalized Medicine**  
**Alberto Villanueva**, ProCURE, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain
- 16:10 Open Debate**
- 16:30 Coffee break**
- 17:00 SESSION 6: STEM CELLS AND MALIGNIZATION**  
Chair: **David Garcia** (ProCURE, ICO, IDIBELL)
- 17:00 The Role of Tumor Initiating Cells in the Inhibition of mTOR in HCC**  
**George Thomas**, Bellvitge Biomedical Research Institute, IDIBELL, L'Hospitalet de Llobregat, Spain
- 17:25 New Pre-clinical Models to study Target-directed Drugs in advanced Colorectal Cancer**  
**Hector G. Palmer**, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 17:50 Deciphering Resistance to Anti-angiogenic Therapies for Prediction of Response and New Treatments**  
**Oriol Casanovas**, ProCURE, Catalan Institute of Oncology (ICO, IDIBELL), Barcelona, Spain
- 18:15 Open Debate**
- 18:40 Closing and Conclusions**

COORGANIZED BY:



WITH THE COLLABORATION OF:

